Johnnie Woodson, MD
Dermatology · Rancho Cucamonga, CANPI 1780727750
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $71,580 of the $109,252 with a category attached, or 65.5%. 32 manufacturers reported payments, led by AbbVie at 44.4% of the total. Reporting peaked in 2019 at $81,143 and has fallen 99.4% since, to $512 in 2025. Among dermatology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 462 payments — averaging $236.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$48K
- Novartis$19K
- Bristol Myers Squibb$18K
- UCB, Inc.$10K
- Amgen$6K
- UCB Biosciences Inc.$4K
- plus $4K from 26 others
Across 120 payments — averaging $7287.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$428K
- AbbVie$100K
- Bausch Health US, LLC$92K
- Janssen Research & Development, LLC$71K
- UCB SA$47K
- VYNE Pharmaceuticals Inc.$40K
- plus $98K from 6 others
What the payments were for
- Consulting fees$11,90011%
- Speaking & faculty fees$71,58066%
- Travel & lodging$15,27014%
- Food & beverage$10,2789%
- Education$2230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 118 | $48,480 |
| Novartis | 50 | $18,522 |
| Bristol Myers Squibb | 39 | $18,280 |
| UCB, Inc. | 69 | $10,093 |
| Amgen | 19 | $5,851 |
| UCB Biosciences Inc. | 22 | $4,385 |
| Johnson & Johnson | 41 | $648 |
| EPI Health, LLC | 1 | $500 |
| Sanofi | 14 | $332 |
| Lilly USA, LLC | 12 | $310 |
| Pfizer | 13 | $248 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 7 | $197 |
| LEO Pharma Inc. | 8 | $188 |
| Sun Pharmaceutical Industries Inc. | 6 | $179 |
| E.r. Squibb & Sons, L.L.C. | 5 | $140 |
| Regeneron Healthcare Solutions, Inc. | 6 | $123 |
| Ipsen Biopharmaceuticals, Inc | 1 | $114 |
| Biofrontera Inc. | 5 | $114 |
| Incyte Corporation | 4 | $89 |
| Galderma Laboratories, L.p. | 3 | $66 |
| Janssen Scientific Affairs, LLC | 1 | $62 |
| Arcutis Biotherapeutics, Inc. | 3 | $60 |
| Mayne Pharma Commercial LLC | 3 | $50 |
| Almirall LLC | 3 | $49 |
| Encore Dermatology Inc. | 2 | $36 |
| VYNE Pharmaceuticals Inc. | 1 | $30 |
| Boehringer Ingelheim | 1 | $27 |
| Fresenius Kabi USA, LLC | 1 | $26 |
| Genentech USA, Inc. | 1 | $16 |
| Taro Pharmaceuticals USA, Inc. | 1 | $15 |
| Promius Pharma LLC | 1 | $11 |
| Prugen, Inc. Pharmaceuticals | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Humira$31,936
- Otezla$23,377
- COSENTYX$15,419
- Skyrizi$14,719
- Cimzia$8,620
- Bimekizumab$1,903
- Sitavig$500
- Cloderm$500
- Minolira 105mg$500
- Minolira 135mg$500
- Rhofade$500
- Bimzelx$125
- DYSPORT$114
How this compares
$109,252 in reported general payments places this provider in the 95th percentile of 1,875 dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 13 | $261,415 |
| Bimzelx AutoinjectorBimekizumab-Bkzx | 12 | $175,779 |
| Dupixent PenDupilumab | 39 | $137,907 |
| Cosentyx Sensoready PenSecukinumab | 12 | $93,455 |
| OpzeluraRuxolitinib Phosphate | 18 | $34,920 |
| Fluorouracil | 234 | $13,783 |
| Clobetasol Propionate | 226 | $5,902 |
| Tacrolimus | 22 | $2,954 |
| Tretinoin | 36 | $2,711 |
| ErythromycinErythromycin Base | 11 | $1,442 |
| Triamcinolone Acetonide | 287 | $1,336 |
| Fluocinonide | 36 | $1,191 |
| Metronidazole | 16 | $977 |
| Econazole Nitrate | 30 | $662 |
| Hydroxyzine Hcl | 111 | $494 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationOpzelura | $89 | $34,92018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,875 dermatology providers in California.
Other dermatology in Rancho Cucamonga
- Paul YamauchiSanta Monica$2.9M
- Jennifer SoungSanta Ana$2.8M
- Robert GreenbergLivermore$2.6M
- Neal BhatiaSan Diego$2.5M
- April ArmstrongLos Angeles$2.3M
- Jeffrey CrowleyBakersfield$2.1M
- Jashin WuCorona$2M
- Raja SivamaniSacramento$1.9M
- Tien NguyenFountain Valley$1.2M
- Tina BhutaniSan Francisco$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.